BioSpace News Archive

Sensei Biotherapeutics, Inc. today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo ® (cemiplimab).

BrainStorm Cell Therapeutics Inc. today announced that Chaim Lebovits , President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 10:30 a.m. PT on Monday, Jan. 9 at Biotech Showcase™ 2023.

Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.

Curative Biotechnology Inc. announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits.

Revolo Biotherapeutics announced that it has completed enrollment and has fully randomized all patients in a Phase 2a clinical study investigating its immune-resetting molecule, ‘1104, for the treatment of patients with allergic disease.

Ventyx Biosciences, Inc. announced that it will host an R&D event on Thursday, January 26, 2023 in New York City from 9-11:30 a.m. ET.

AUM Biosciences Pte. Ltd. announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation for its product candidate, AUM302, a potential first-in-class oral kinase inhibitor that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR, for the treatment of neuroblastoma.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced that Jerry Durso, President and Chief Executive Officer, will give a corporate presentation at the J.P. Morgan 41st Annual Healthcare Conference.

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced the receipt of a $36.4 million milestone payment associated with the second procurement of NUZYRA® (omadacycline) under the company’s Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Thursday, January 12th at 7:30 a.m. PT.